BiotechTube
QurAlis

QurAlis

Cambridge, United States· Est.
quralis.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $226.5M

Overview

QurAlis is a private, clinical-stage biotech pioneering precision therapies for neurodegenerative diseases, primarily ALS and FTD. The company leverages its proprietary FlexASO® antisense oligonucleotide platform and deep understanding of TDP-43 pathology to develop targeted treatments. Its pipeline includes two lead clinical-stage assets: QRL-201, a first-in-class therapy targeting STATHMIN-2 restoration for sporadic ALS, and QRL-101, a selective Kv7.2/7.3 ion channel opener for ALS hyperexcitability, epilepsy, and pain. The company is advancing a biomarker-defined, precision medicine strategy in a high-need therapeutic area.

Amyotrophic Lateral Sclerosis (ALS)Frontotemporal Dementia (FTD)EpilepsyPainNeurodegenerative Diseases

Technology Platform

FlexASO®: A proprietary antisense oligonucleotide (ASO) splice modulator platform designed to correct pathological RNA mis-splicing, particularly that caused by TDP-43 pathology, in neurodegenerative and neurological diseases.

Funding History

4
Total raised:$226.5M
Series B$88M
Series B$88M
Series A$42M
Seed$8.5M

Opportunities

The high unmet need in ALS and related neurodegenerative diseases presents a significant market opportunity for effective precision therapies.
Expansion of QRL-101 into large, established markets like epilepsy and pain provides valuable pipeline diversification and de-risks the platform.
The proprietary FlexASO® platform offers a scalable approach to target multiple diseases driven by RNA splicing defects.

Risk Factors

The company faces high clinical development risk as its novel mechanisms are unproven in late-stage trials.
As a pre-revenue private company, it is dependent on securing additional financing to advance its expensive clinical programs.
The competitive landscape in neurodegeneration is intensifying, with many companies pursuing similar patient populations and targets.

Competitive Landscape

QurAlis operates in the competitive ALS space, facing other biotechs developing ASOs (e.g., Ionis, Biogen with tofersen for SOD1-ALS), small molecules, and gene therapies. Its precision approach targeting specific patient subsets (e.g., STMN2 loss) may carve a distinct niche. In epilepsy/pain, QRL-101 will compete with established and novel ion channel modulators from large pharma and specialized neurology companies.

More companies in United States →